tetradecyldimethylbenzylammonium chloride dihydrate | 283158-20-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: tetradecyldimethylbenzylammonium chloride dihydrate
• 英文别名: benzyldimethyltetradecylammonium chloride dihydrate；Benzyldimethyltetradecylammonium chloride hydrate；benzyl-dimethyl-tetradecylazanium;chloride;hydrate
• CAS: 283158-20-3
• 化学式: C₂₃H₄₂N*Cl*2H₂O
• 分子量: 404.077
• InChiKey: FXJNQQZSGLEFSR-UHFFFAOYSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  3.14
• 重原子数：
  26
• 可旋转键数：
  15
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.74
• 拓扑面积：
  1
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  tetradecyldimethylbenzylammonium chloride dihydrate 、 potassium thioacyanate 、 mercury(II) nitrate 以 硝酸 为溶剂， 生成 tetradecyldimethylbenzylammonium thiocyanatomercurate(II)
  参考文献：
  名称：

  Zephiramine小规模离子对萃取后石墨炉原子吸收光谱法测定汞

  摘要：

  描述了通过石墨炉原子吸收光谱法测定汞 (II) 的简单程序。使用 10 cm3 离心管将汞（II）以十四烷基二甲基苄基铵（Zephiramine）硫代氰基汞酸盐（II）的形式提取到二异丁基酮（DIBK）中，然后从离心管的上层直接移出等分的有机提取物，注入石墨炉。斜坡模式的加热温度程序和2通道型原子吸收光谱仪的背景校正给出了令人满意的结果。

  DOI：

  10.1246/bcsj.60.3053
• 作为试剂：
  描述：

  黄樟素 在 potassium permanganate 、 tetradecyldimethylbenzylammonium chloride dihydrate 、 溶剂黄146 作用下， 以 水 、 丙酮 、 苯 为溶剂， 反应 72.0h， 以58%的产率得到胡椒乙酸
  参考文献：
  名称：

  Synthesis and antitumour evaluation of peptidyl-like derivatives containing the 1,3-benzodioxole system

  摘要：

  In the scope of a research program aiming at the synthesis and pharmacological evaluation of novel possible antitumour prototype compounds, we described in this paper the synthesis of peptidyl-like derivatives containing the 1,3-benzodioxole system. The proliferation inhibitors tested against tumour cell lines identified the derivatives tyrosine (4f) and lysine (4g) as the most active among them, presenting IC50 values in micromolar range and are more active than Safrole. For the study on the embryonic development, Safrole did not show any selectivity in this latter assay, which indicates that Safrole acts as a 'cell cycle-nonspecific' inhibitory agent. However, compound M presented a fair antimitotic effect, mainly on third cleavage and blastulae stages (38% and 1.7% of normal development, at 10 mu g/mL), suggesting a time-dependent activity and a 'cell cycle-specific' agent action. Neither derivatives revealed hemolytic action in assay with mouse erythrocytes. (c) 2006 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2006.10.007

文献信息

• [EN] HALOGENATED HETEROALKENYL- AND HETEROALKYL-FUNCTIONALIZED ORGANIC COMPOUNDS AND METHODS FOR PREPARING SUCH COMPOUNDS<br/>[FR] COMPOSÉS ORGANIQUES HALOGÉNÉS À FONCTION HÉTÉROALCÉNYLE ET HÉTÉROALKYLE ET LEURS PROCÉDÉS DE PRÉPARATION
  申请人：ARKEMA INC

  公开号：WO2019067394A1

  公开（公告）日：2019-04-04

  A method for synthesizing halogenated organic compounds, such as halogenated alkenyl group-containing and halogenated alkyl group-containing compounds having a heteroatom (e.g., O,N.S) coupled to a carbon atom of a halogenated alkenyl or halogenated alkyl group, involves reacting a halogenated olefin such as a chloro-substituted trifluoropropenyl compound with an active hydrogen-containing organic compound such as an alcohol (e.g., an aliphatic monoalcohol, aliphatic polyalcohol, or a phenolic compound), a primary amine, a secondary amine or a thiol.

  合成卤代有机化合物的方法，例如含卤代烯基基团和含卤代烷基基团的化合物，其中含有一个杂原子（例如，O，N，S）与卤代烯基或卤代烷基基团的碳原子偶联，涉及将卤代烯烃（例如氯代三氟丙烯基化合物）与含有活性氢的有机化合物（例如醇（例如脂肪族单醇，脂肪族多醇或酚类化合物），一级胺，二级胺或硫醇）反应。
• [EN] APP SPECIFIC BACE INHIBITORS (ASBIs) AND USES THEREOF<br/>[FR] INHIBITEURS DE BACE SPÉCIFIQUES DE L'APP (ASBI) ET LEURS UTILISATIONS
  申请人：JOHN VARGHESE

  公开号：WO2013142370A1

  公开（公告）日：2013-09-26

  In certain embodiments APP-specific BACE inhibitors (ASBIs) are provided as well as uses thereof. In certain embodiments methods of preventing or delaying the onset of a pre-Alzheimer's condition and/or cognitive dysfunction, and/or ameliorating one or more symptoms of a pre-Alzheimer's condition and/or cognitive dysfunction, or preventing or delaying the progression of a pre-Alzheimer's condition or cognitive dysfunction to Alzheimer's disease are provided where the method involves administering to a subject in need thereof an APP specific BACE inhibitor (ASBI) in an amount sufficient to prevent or delay the onset of a pre-Alzheimer's cognitive dysfunction, and/or to ameliorate one or more symptoms of a pre-Alzheimer's cognitive dysfunction, and/or to prevent or delay the progression of a pre-Alzheimer's cognitive dysfunction to Alzheimer's disease. In certain embodiments the ASBI is a flavonoid (e.g. galangin) or flavonoid progrug (e.g., galangin prodrug).

  在某些实施例中，提供了特定于APP的BACE抑制剂（ASBI）以及其用途。在某些实施例中，提供了预防或延迟早期阿尔茨海默病症状和/或认知功能障碍的方法，以及改善早期阿尔茨海默病症状和/或认知功能障碍的一种或多种症状，或预防或延迟早期阿尔茨海默病症状或认知功能障碍发展为阿尔茨海默病的方法，其中该方法涉及向需要的受试者施用足以预防或延迟早期阿尔茨海默病认知功能障碍发作的APP特异性BACE抑制剂（ASBI）的剂量，和/或改善早期阿尔茨海默病认知功能障碍的一种或多种症状，和/或预防或延迟早期阿尔茨海默病认知功能障碍发展为阿尔茨海默病。在某些实施例中，ASBI是一种黄酮类化合物（例如，没药酮）或黄酮类化合物前药（例如，没药酮前药）。
• [EN] MTORC MODULATORS AND USES THEREOF<br/>[FR] MODULATEURS DE MTORC ET LEURS UTILISATIONS
  申请人：AEOVIAN PHARMACEUTICALS INC

  公开号：WO2020154447A1

  公开（公告）日：2020-07-30

  Novel rapamycin analogs and uses thereof are disclosed herein. The rapamycin analogs of the present disclosure show increased mTORC1 specificity and lowered mTORC2 specificity relative to rapamycin.

  本文披露了新型雷帕霉素类似物及其用途。本公开的雷帕霉素类似物相对于雷帕霉素表现出增加的mTORC1特异性和降低的mTORC2特异性。
• [EN] HYDANTOINS THAT MODULATE BACE-MEDIATED APP PROCESSING<br/>[FR] HYDANTOÏNE MODULANT LE TRAITEMENT D'APP MÉDIÉ PAR BACE
  申请人：BUCK INST FOR RES ON AGING

  公开号：WO2014127042A1

  公开（公告）日：2014-08-21

  In certain embodiments hydantoin compounds are provided herein that are effective to inhibit BACE activity against APP. Without being bound to a particular theory, it is believed the activity of the hydantoins identified herein appears to be associated with binding to BACE and/or to APP particularly when these moieties form a BACE/APP complex. Accordingly, it is believed the compounds described herein represent a new class of compounds designated herein as APP-Binding-BACE Inhibitors (ABBIs) and provide a new mechanism to modulate APP processing. The hydantoins described herein appear to show improved brain permeability and functional BACE inhibition.

  在某些实施例中，本文提供了一些有效抑制BACE对APP活性的咪唑烷酮化合物。在没有受限于特定理论的情况下，据信此处识别的咪唑烷酮的活性似乎与结合到BACE和/或APP有关，特别是当这些基团形成BACE/APP复合物时。因此，据信本文描述的化合物代表了一类新的化合物，被称为APP结合BACE抑制剂（ABBIs），并提供了一种新的机制来调节APP的加工。这里描述的咪唑烷酮似乎显示出改善的脑透过性和功能性BACE抑制作用。
• [EN] APOE4-TARGETED THERAPUTICS THAT INCREASE SIRT1<br/>[FR] AGENTS THÉRAPEUTIQUES CIBLÉS SUR L'APOE4 QUI ACCROISSENT SIRT1
  申请人：UNIV CALIFORNIA

  公开号：WO2016028910A1

  公开（公告）日：2016-02-25

  A link between ApoE4 allele and sirtuins expression level is identified that is believed to be associated with elevated risk for the promotion of processing of amyloid precursor protein (APP) by the non-amyloidogenic pathway in a mammal leading to elevated risk for Alzheimer's disease. Compounds are identified that upregulate sirtuins (e.g., SirT1) expression levels and appear to be useful in the treatment and/or prophylaxis of MCI and/or Alzheimer's disease.

  已确定了ApoE4等位基因与sirtuins表达水平之间的联系，据信与促进哺乳动物中非淀粉样途径下淀粉样前体蛋白（APP）的加工有关，从而导致患老年痴呆症的风险增加。已确定了一些化合物，可以上调sirtuins（例如SirT1）的表达水平，并且似乎在治疗和/或预防轻度认知障碍和/或老年痴呆症方面很有用。